The Technical Analyst
Tiziana Life Sciences PLC [TLSA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Tiziana Life Sciences PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.95% $0.790
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 79.48 mill |
| EPS: | -0.150 |
| P/E: | -5.27 |
| Earnings Date: | Dec 25, 2023 |
| SharesOutstanding: | 100.59 mill |
| Avg Daily Volume: | 0.150 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 2/22 | 4/22 | 4/22 | 2/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.27 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.90x |
| Company: PE -5.27 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.224 (-71.64%) $-0.566 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.746 - 0.824 ( +/- 4.97%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.788
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.788
Forecast 2: 16:00 - $0.788
Forecast 3: 16:00 - $0.788
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.790 (1.95% ) |
| Volume | 0.331 mill |
| Avg. Vol. | 0.150 mill |
| % of Avg. Vol | 220.18 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TLSA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TLSA
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Latest Press Releases
2024-04-23 07:00:00 - Press Release
Tiziana Life Sciences Announces Fda Allowance For Additional Twenty Patients To Be Enrolled In The Intranasal Foralumab Multiple Sclerosis Expanded Access Program
New york, april 23, 2024 (globe newswire) -- tiziana life sciences, ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the u.s. food and drug administration (fda) has allowed its intranasal foralumab non-active secondary progressive multiple sclerosis (na-spms) expanded access (ea) program to expand from 10 patients to a total of 30 patients.
2024-04-22 07:00:00 - Press Release
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients In Its Expanded Access Program
New york, april 22, 2024 (globe newswire) -- tiziana life sciences, ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced additional positive clinical results from its intermediate sized expanded access program (eap) for non-active secondary progressive multiple sclerosis (na-spms) patients. the data demonstrate multiple improvements in foralumab-treated patients, with 70% showing an improvement in fatigue after six months of follow-up. fatigue is a debilitating symptom for many ms patients and is measured by the modified fatigue impact scale (mfis).
2024-04-19 07:00:00 - Press Release
Tiziana Life Sciences Announces Study Results From Intranasal Anti-cd3 Foralumab In Multiple Sclerosis Patients With Pira Highlighted In Neurology Today®
- intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (pira) - - data presented in a platform session at the annual meeting of the american academy of neurology in denver, colorado -
2024-04-18 07:00:00 - Press Release
Tiziana Life Sciences Announces New Quantitative Pet Imaging Data On Foralumab At The Annual Meeting Of The American Academy Of Neurology
Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (ms) patients with pira as measured by changes in pet scans oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (ms) patients with pira as measured by changes in pet scans
2024-04-11 07:00:00 - Press Release
Tiziana Life Sciences Announces Platform Presentation Of New Quantitative Pet Imaging Data On Foralumab At The Annual Meeting Of The American Academy Of Neurology
New york, april 11, 2024 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa ) (“tiziana” or the “company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, “treatment of pira with nasal foralumab dampens microglial activation and stabilizes clinical progression in non-active secondary progressive ms” that will be presented during the “multiple sclerosis: therapeutics and clinical decision making” session at the annual meeting of the american academy of neurology, to be held april 13-18, 2024 in denver, colorado.
Latest News
2024-04-23 08:43:55 - Proactive Investors
Tiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access Program
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been approved by the US Food and Drug Administration to expand patient enrollment in its non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access Program. The company said it will expand the program, which is evaluating its investigative therapeutic intranasal foralumab, from 10 patients to 30.
2024-04-22 08:49:54 - Proactive Investors
Tiziana Life Sciences reports additional positive results from Multiple Sclerosis program
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled additional positive results from its Expanded Access Program for patients with non-active secondary progressive multiple sclerosis (na-SPMS). The clinical-stage biopharmaceutical company said patients treated with its investigative therapeutic intranasal foralumab demonstrated multiple improvements, with 70% showing an improvement in fatigue after six months of follow-up.
2024-04-19 09:09:01 - Proactive Investors
Tiziana Life Sciences' foralumab study highlighted in Neurology Today
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its study on foralumab, the company's lead candidate, was published in Neurology Today, the esteemed news source of the American Academy of Neurology (AAN). The study sheds light on foralumab's potential in attenuating microglial activation in non-active secondary progressive multiple sclerosis (na-SPMS) patients with progression independent of relapse (PIRA).
2024-04-18 09:30:20 - Proactive Investors
Tiziana Life Sciences says foralumab shows promise in stabilizing certain types of MS
Tiziana Life Sciences Ltd (NASDAQ:TLSA) unveiled new quantitative PET imaging data on foralumab at the Annual Meeting of the American Academy of Neurology in Denver. The company presented data from its platform presentation titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS.
2024-04-11 09:11:03 - Proactive Investors
Tiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conference
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will be presenting new data about its lead clinical asset foralumab at the Annual Meeting of the American Academy of Neurology being held from April 13 to 18 in Denver, Colorado. The company said the oral presentation, titled “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS,” will be part of the “Multiple Sclerosis: Therapeutics and Clinical Decision Making” session.
2024-03-05 08:27:07 - Proactive Investors
Tiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's disease
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that chairman of its Scientific Advisory Board Dr. Howard Weiner will present positive data on intranasal anti-CD3 monoclonal antibody (mAb) in models of Alzheimer's and Parkinson's disease at an upcoming conference.
2024-01-08 08:31:59 - Proactive Investors
Tiziana Life Sciences reveals positive clinical, PET scan findings for intranasal Foralumab in MS patients
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients, which have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). The clinical-stage biopharmaceutical company said PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period.
2024-01-05 09:30:00 - GlobeNewsWire
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024.
2024-01-05 08:08:55 - Proactive Investors
Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has filed a new patent application relating to the composition and methods for combining a GLP-1 receptor agonist (ra) and foralumab, its lead drug candidate, to further reduce system and vascular inflammation associated with Type 2 diabetes (T2D) and also in patients with non-T2D obesity. The company said that the patent application describes the potential for foralumab, which is a fully human anti-CD3 antibody, to provide additional risk reduction for heart attack, stroke, and peripheral vascular disease when combined with a GLP-1ra in this patient population.
2023-12-19 08:56:16 - Proactive Investors
Tiziana Life Sciences doses first patient in mid-stage multiple sclerosis study
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the first patient has been dosed in its Phase 2a study which is comparing two doses of its investigational therapeutic intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). The trial involves six investigational centers which will recruit up to 18 patients per treatment arm.